AbbVie’s Rinvoq marches toward blockbuster ulcerative colitis nod even as JAK delays drag on
AbbVie has pegged much of its post-Humira hopes on its next-gen immunology med Rinvoq, which now appears one step closer toward what could be a $ 2 billion indication in ulcerative colitis. The Chicago-based pharma said on Tuesday that its rheumatoid arthritis drug “significantly” topped placebo at helping moderate to severe ulcerative colitis patients reach clinical remission after… Read More »